Key result
The PRASFIT-Elective angioscopic substudy evaluated the incidence of stent thrombosis in Japanese patients undergoing elective PCI receiving prasugrel or clopidogrel, but no results were reported.
Why the study?
Does prasugrel or clopidogrel reduce intrastent thrombus formation in Japanese patients undergoing elective PCI?
RCT
Does prasugrel or clopidogrel reduce intrastent thrombus formation in Japanese patients undergoing elective PCI?
In Japanese patients undergoing elective PCI, dual antiplatelet therapy with prasugrel or clopidogrel was associated with a reduction in red intrastent thrombi over 36 weeks, with favorable stent coverage.
Answers are grounded in this paper and cite their sources.
Unreported stent thrombosis incidence leaves prasugrel-clopidogrel comparison open in elective PCI; further complete analyses needed.
Background: Angioscopy was performed in a group of patients in the PRASugrel For Japanese PatIenTs with Coronary Artery Disease Undergoing Elective PCI (PRASFIT-Elective) study to determine the incidence and clinical features of stent thrombosis. Stent thrombosis is an infrequent, but potentially severe event that may require revascularization or lead to other clinically significant events. Its incidence and clinical features in Japanese patients undergoing elective percutaneous coronary intervention (PCI) are poorly understood, especially in those receiving dual antiplatelet therapy with prasugrel or clopidogrel in combination with aspirin.
No takes yet. Share an insight, caveat, or question.
Ueno et al. (2018) conducted an RCT in Coronary Artery Disease. Prasugrel vs. Clopidogrel was evaluated on Incidence and clinical features of stent thrombosis. The PRASFIT-Elective angioscopic substudy evaluated the incidence of stent thrombosis in Japanese patients undergoing elective PCI receiving prasugrel or clopidogrel, but no results were reported.
Synapse has enriched 10 related papers. Consider them for comparative context: